Business Wire

CA-VEEVA-SYSTEMS-INC.

16.9.2020 13:05:07 CEST | Business Wire | Press release

Share
More Than 500 Clinical Research Sites Adopt Veeva SiteVault to Accelerate Research

Accelerating clinical research is a top priority across sites, sponsors, and CROs. To help speed research, more sites are using Veeva SiteVault Free for managing study documentation and collaborating remotely with study monitors. In eight months since the product has been available from Veeva Systems (NYSE: VEEV), the number of SiteVault Free customers has increased to more than 500 in over 30 countries, signaling a rapid shift among global research sites to simplify and streamline study execution.

“Sites see a tremendous opportunity to reduce the time and effort in managing regulatory binders and improve how they share study information with sponsors,” said Bree Burks, RN, MSN, vice president of site strategy at Veeva and a former clinical research director. “We’re proud to support research sites around the world, making study execution and compliance easier so they can focus on important research and patient care.”

Veeva SiteVault eliminates manual and paper-based processes with a modern application to manage regulatory and source documentation compliant with 21 CFR Part 11 and HIPAA requirements. Capabilities such as electronic signatures, certified copy workflows, and reporting simplify compliance. With remote monitoring, sites can give study monitors secure and direct access to study binders from any location and streamline collaboration throughout every stage of source document review and verification.

Veeva SiteVault Free can be used for all trials regardless of what technology sponsors are using, as well as the site file for investigator-initiated trials. The application is free for clinical research sites and comes with full training and support.

For more information or to sign-up for SiteVault Free, visit sites.veeva.com . To learn more about remote monitoring, see a demo at sites.veeva.com/RemoteMonitoring .

What Sites are Saying About Veeva SiteVault Free

“We are reducing study activation timelines by 40%, spending half the time completing regulatory tasks, and saving tens of thousands of dollars per study with Veeva SiteVault Free,” said Justin Deck, chief clinical officer at Tilda Research. “Veeva has helped us dramatically improve the speed and efficiency of study execution for more than 50 studies across 18 different sponsors.”

“Our 4-hour in-person monitoring visits are now just 30 minutes using remote monitoring in Veeva SiteVault Free,” said Charles Sydnor, project manager at Crofoot Research Center. “The simplicity of the application makes it easy to collaborate remotely with study monitors. There’s also less administrative burden to maintain compliance, allowing our team to spend more time on patient care.”

“COVID-19 halted onsite visits just as we were in the process of locking our study database,” said Hanna Voltattorni, senior project manager at CNS, the largest clinical research provider in southern California. “Veeva allowed us to continue working with study monitors and keep the trial going. We are now using Veeva SiteVault Free across all our studies.”

“Veeva’s support and site-centric approach has streamlined our study processes and made operations much more efficient,” said Megan Ford, executive director, clinical trials at the Ingham Institute for Applied Medical Research. “We have now standardized on Veeva SiteVault Free across our research departments in all hospitals to simplify and streamline research.”

About Veeva SiteVault
Veeva SiteVault reduces the administrative burden of managing regulatory and source documents across all trials with capabilities such as remote monitoring, electronic signatures, certified copy workflows, and reporting. Available in two editions, SiteVault Free comes with full training and support, and SiteVault Enterprise provides customized reports, tailored workflows, and open APIs for integrations. For more information about Veeva SiteVault or to sign-up for SiteVault Free, visit sites.veeva.com .

Additional Information
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems

About Veeva Systems
Veeva Systems Inc. is a leader in cloud solutions—including data, software, and services—for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 900 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. The company is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu .

Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov . Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Microsoft and Postel: An Innovative New Data and AI-Driven Solution to Optimize Italian SMEs' Relationships with Their Customers28.4.2026 07:00:00 CEST | Press release

Microsoft and Postel, a Poste Italiane Group company, announce an evolution of their collaboration and of the agreements they have signed for the digitalization of Italian businesses, welcoming Audiencerate as technology partner in the Data and Direct & Digital Marketing space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427013396/en/ The Marketing Data Platform combines AI-powered market intelligence, first-party data and omnichannel activation to help SMEs analyze market trends and historical campaign performance, turning insights into audiences and increasingly targeted future actions. The agreement provides for the distribution of an integrated platform that combines Postel's omnichannel physical-and-digital communication capabilities with Audiencerate'sdata intelligence functionalities and Microsoft's AI and Cloud solutions. The solution enables SMEs to leverage and activate their own data across the entire custom

LTM Launches BlueVerse™ Studio as a Hub for Enterprise Agentic AI Adoption28.4.2026 07:00:00 CEST | Press release

Showcasing AI capabilities to solve real‑world client challenges LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of its BlueVerse Studio in Bengaluru, a hub designed to accelerate Enterprise Agentic AI adoption for clients and deliver measurable business outcomes. LTM continues to launch more studios globally to drive AI innovation and also has studios in London and Mumbai. As part of the company’s ongoing investment in bringing innovation closer to clients, the BlueVerse Studio was created to help clients scale AI solutions from experiments to practical applications while ensuring trust and control. It unites LTM’s strongest AI capabilities, including BlueVerse CraftStudio, physical AI showcases, and industry-centric AI offerings, within one ecosystem along with: Multiple BlueVerse-certified consulting and delivery professionals currently support enterprise-grade AI solutions. These certifications provide expertise in developing inte

Helical Fusion Launches Helix Program “Official Partners” to Build Japan’s Industrial Coalition for Commercial Fusion Energy28.4.2026 05:00:00 CEST | Press release

Multiple long-established Japanese companies join as inaugural partners in a shared push to build the fusion energy industry; Helical Fusion also completed the first close of its Series B round Helical Fusion Co., Ltd., a fusion energy company developing a Helical stellarator power plant, today announced the launch of Helix Program Official Partners, a new strategic partnership framework designed to bring together long-term industrial collaborators committed to advancing fusion from laboratory progress to real-world fusion power deployment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427596284/en/ Helical Fusion’s Integrated Demonstration Device, “Helix HARUKA,” currently under construction (photographed at the company’s dedicated workspace within the National Institute for Fusion Science in Gifu, Japan) The Helix Program is Helical Fusion’s core initiative to realize commercially viable fusion energy in the 2030s. Rat

Investor Supporting Japan’s Entertainment Industry, Yoshihiro Shimamura, to Visit France Workshop to be Held During the Cannes Film Festival28.4.2026 04:00:00 CEST | Press release

Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of Hankyu Hanshin Holdings, Inc.—a major Japanese entertainment conglomerate known for producing content enjoyed across generations—and became a major shareholder (as of March 25, 2026). Through such investments, the company aims to support the global expansion of Japanese entertainment while exploring synergies with its own interna

Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release

Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye